Login to Your Account



Let's Make a Deal

Differentiation Makes a Difference In Biopharma Partnering Success

By Marie Powers
Staff Writer

Friday, September 21, 2012
us_resized.jpg

BOSTON – A common refrain heard last week at BioPharm America 2012 in Boston was the need for biotechs to consider partnering opportunities at every step along the path to commercialization, from preclinical to post-approval. The optimum success strategy? In a word: Differentiate.

Epizyme Inc. banked $135 million in up-front and milestone payments from three partnerships before it moved lead compound EPZ-5676, a small-molecule inhibitor of histone methyltransferase (HMT) DOT1L, into a Phase I study earlier this month.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription